Kyverna Therapeutics Reports Director/Officer Changes & Financials
Ticker: KYTX · Form: 8-K · Filed: Sep 25, 2025 · CIK: 1994702
Sentiment: neutral
Topics: management-change, financials, corporate-governance
Related Tickers: KYTX
TL;DR
Kyverna's 8-K: New directors/officers appointed, financial statements filed. Watch for leadership impact.
AI Summary
Kyverna Therapeutics, Inc. filed an 8-K on September 25, 2025, reporting events as of September 19, 2025. The filing pertains to the departure and election of directors, appointment of officers, and compensatory arrangements. It also includes financial statements and exhibits.
Why It Matters
This filing indicates potential shifts in the company's leadership and governance structure, which could impact strategic direction and operational oversight.
Risk Assessment
Risk Level: medium — Changes in directors and officers, along with the filing of financial statements, can signal internal shifts or upcoming strategic moves that may affect the company's performance.
Key Numbers
- 001-41947 — SEC File Number (Identifies the company's filing record with the SEC.)
- 83-1365441 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Kyverna Therapeutics, Inc. (company) — Registrant
- September 19, 2025 (date) — Earliest event date
- September 25, 2025 (date) — Date of report
- 001-41947 (company) — SEC File Number
- 83-1365441 (company) — IRS Employer Identification No.
FAQ
What specific changes occurred regarding directors or officers?
The filing indicates the departure of directors or certain officers and the election of directors and appointment of certain officers, as detailed in Item 5.02.
What is the exact date of the earliest event reported?
The earliest event reported is dated September 19, 2025.
What type of financial information is included in this filing?
The filing includes financial statements and exhibits, as indicated by Item 9.01.
What is the company's principal executive office address?
The principal executive offices are located at 5980 Horton St., Suite 550, Emeryville, California 94608.
What is the company's state of incorporation?
Kyverna Therapeutics, Inc. is incorporated in Delaware.
Filing Stats: 516 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2025-09-25 16:05:29
Key Financial Figures
- $0.00001 — ch registered Common Stock, par value $0.00001 per share KYTX The Nasdaq Stock Mar
Filing Documents
- kytx-20250919.htm (8-K) — 44KB
- 0001193125-25-217434.txt ( ) — 147KB
- kytx-20250919.xsd (EX-101.SCH) — 24KB
- kytx-20250919_htm.xml (XML) — 5KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KYVERNA THERAPEUTICS, INC. Date: September 25, 2025 By: /s/ Warner Biddle Warner Biddle Chief Executive Officer